Zolgensma in United Arab Emirates

Zolgensma - overview

Zolgensma (onasemnogene abeparvovec) is manufactured by Novartis and indicated for Spinal muscular atrophy. It is a Gene therapy (AAV) approved by the US FDA in 2019 and may be accessible to patients in United Arab Emirates through a Named Patient Program or personal-import pathway.

Access in United Arab Emirates

The UAE recognises a formal Named Patient / compassionate-use pathway via MOHAP and the Department of Health Abu Dhabi (DoH). Physicians apply on behalf of individual patients for drugs not registered in-country.

How Reserve Meds coordinates access in United Arab Emirates

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and United Arab Emirates-specific eligibility.
3. Treating physician in United Arab Emirates issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Zolgensma from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in United Arab Emirates.

Typical timeline for United Arab Emirates

End-to-end, most requests are completed in 2-6 weeks. United Arab Emirates's tier 1 regulatory maturity typically supports fast processing times.

What patients and physicians in United Arab Emirates ask

• Is the pathway legal in United Arab Emirates? Yes - it operates under United Arab Emirates's established NPP or personal-import framework.
• Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
• What physician credentials do I need? A licensed physician in United Arab Emirates able to issue the prescription and clinical justification.
• What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
• Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Zolgensma in United Arab Emirates

Request Zolgensma